MZL

7 registered clinical trials studyying MZL — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma NCT07492407	Henan Cancer Hospital	—
Not Yet Recruiting	Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma NCT07459608	Henan Cancer Hospital	Phase 2
Recruiting	Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma NCT06510309	Gottfried von Keudell, MD PhD	Phase 2
Not Yet Recruiting	Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human NCT07259070	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Withdrawn	HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691	Hutchmed	Phase 1
Completed	A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) NCT03797456	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 2
Completed	Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma NCT03846427	BeiGene	Phase 2